Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Rapid Communications

Rapid Communications 3: Thyroid 1

ea0081rc3.1 | Rapid Communications 3: Thyroid 1 | ECE2022

Usefulness of the EU-TIRADS score on sparing thyroid nodules cytology: a retrospective study

Puga Francisca , Silva Vânia Benido , Carvalho Andre , Freitas Claudia

Introduction: Incidental diagnosis of thyroid nodules has increased in recent years, leading to thyroid cancer diagnosis inflation. Nonetheless, mortality rate for thyroid malignancies remains very low, suggesting that its treatment is unlikely to affect the overall prognosis in the majority of cases. Several thyroid imaging scores have been proposed to reduce unnecessary invasive diagnostic procedures. Our aim was to verify the usefulness of the EU-TIRADS score on sparing thy...

ea0081rc3.2 | Rapid Communications 3: Thyroid 1 | ECE2022

Performance of a raman fingerprint in thyroid nodules with indeterminate cytology: a prospective blinded monocentric study

Palermo Andrea , Sodo Armida , Mihaela Naciu Anda , Di Gioacchino Michael , Paolucci Alessio , Di Masi Alessandra , Maggi Daria , Crucitti Pierfilippo , Longo Filippo , Perrella Eleonora , Taffon Chiara , Verri Martina , Antonietta Ricci Maria , Crescenzi Anna

Background: Molecular analysis of thyroid fine-needle aspiration biopsy (FNA) was proposed to improve indeterminate nodules management. However, sensibility and specificity as well as the cost of molecular diagnostics require to be improved to increase their cost-effectiveness for medical practice setting. Raman spectroscopy (RS) demonstrated ability in separating benign from malignant thyroid lesions in surgically removed tissues, based on specific RS profile. This study aime...

ea0081rc3.3 | Rapid Communications 3: Thyroid 1 | ECE2022

Tailoring the diagnostic indication to radioactive iodine treatment in differentiated thyroid cancer- novel biomarkers

Buczyńska Angelika , Kościuszko Maria , Sidorkiewicz Iwona , Adamska Agnieszka , Siewko Katarzyna , Krętowski Adam , Popławska-Kita Anna

Differentiated thyroid cancer (DTC) is the most common malignant neoplasm arising from the thyroid parenchymal cells. DTC incidence is steadily increasing worldwide and there are approximately 1700 new cases/per year in Poland. The biopsy with subsequent thyroid resection plays a central role in the diagnosis and treatment of this malignancy. After surgery, radioactive iodine (RAI) treatment is recommended to eradicate potential residual disease and improve prognosis. Due to t...

ea0081rc3.4 | Rapid Communications 3: Thyroid 1 | ECE2022

Are BRAF-TERT mutated differentiated thyroid cancers similar to other double mutated?

Colapinto Alessandra , Basso Cristina , Vicennati Valentina , Cavicchi Ottavio , Lodi Rizzini Elisa , Golemi Arber , Tabacchi Elena , Nannini Margherita , De Biase Dario , De Leo Antonio , Tallini Giovanni , Pagotto Uberto , Repaci Andrea

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

ea0081rc3.5 | Rapid Communications 3: Thyroid 1 | ECE2022

Impact of stimulated thyroglobulin and BRAF status in Stage I and ATA intermediate risk DTC

Basso Cristina , Colapinto Alessandra , Vicennati Valentina , Pagotto Uberto , Tallini Giovanni , De Leo Antonio , De Biase Dario , Lodi Rizzini Elisa , Cavicchi Ottavio , Nannini Margherita , Tabacchi Elena , Golemi Arber , Repaci Andrea

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...

ea0081rc3.6 | Rapid Communications 3: Thyroid 1 | ECE2022

The mRNA of fibronectin 1 and of the integrin subunit alpha V are powerful prognostic indicators in papillary thyroid carcinoma

Vitale Mario , Marotta Vincenzo , Tortora Anna , Izzo Giulia , Rocco Domenico

Integrins are cell-extracellular matrix adhesion molecules considered functionally related to the development of cancer metastasis. Starting from the dataset of mRNA-seq of papillary thyroid carcinoma (PTC) from the TCGA, we determined the expression of fibronectin 1 (FN1) and fibronectin-binding integrins in PTC. We then analyzed the association of the expression of these two genes with the driver genes, the stage of the disease and its outcome. 355 PTCs and 58 normal thyroid...

ea0081rc3.7 | Rapid Communications 3: Thyroid 1 | ECE2022

Immune-related thyroid dysfunctions during PD-1/PD-L1 inhibitors and their association to the oncological outcome: new evidence

Ferrari Matteo , Anna Nervo Alice , Basile Sara , Migliore Enrica , D'Angelo Valentina , Gruosso Giovanni , Rosso Daniela , Retta Francesca , Piovesan Alessandro , Arvat Emanuela

Background: Immune checkpoint inhibitors (ICIs) showed impressive results in several malignancies; however, a large spectrum of immune-related adverse events (IRAEs) may occur, including thyroid dysfunction (DYSTHYR). IRAEs seem to be associated with better cancer outcome; limited data suggested that thyroid toxicity could be a predictor of response to ICIs.Patients and methods: We retrospectively evaluated all patients who started treatment with the pro...